RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
CC-Pharming of Beijing paid $4.7 million to form a joint commercial relationship with Texas’ iBio using iBio’s plant-based technology to develop and manufacture antibodies. The first product will be a bio-better biosimilar to rituximab, a Roche drug that is used to treat autoimmune diseases and certain cancers. iBio says its plant-based technology cuts costs and reduces time-to-validation compared to the usual animal cell methods. CC-Pharming could add other antibodies at a later date, which would trigger additional payments.
Source: China Biotoday
